The SanBio Group announcde that Masahito Kawabori, Specially Appointed Associate Professor of the Department of Neurosurgery and Neuronal Cell Therapy, Hokkaido University Hospital presented the results of the global Phase 2 clinical trial of SB623 targeting chronic effects associated with traumatic brain injury (STEMTRA study) during Symposium 3, Brain Protection and Regenerative Medicine, of the 44th Annual Meeting of the Japan Society of Neurotraumatology in Takamatsu, Kagawa Prefecture. The STEMTRA study was a randomized, double-blind, surgical sham-controlled, global Phase 2 trial to evaluate the efficacy and safety of SB623 in patients with chronic motor deficit resulting from traumatic brain injury. The primary endpoint of the study was met, with patients who received SB623 demonstrating statistically significant improvement in motor functions compared to the control group patients who received sham surgery. Further, interim analysis based on data obtained six months after the administration of SB623 or sham surgery indicated that SB623 was well-tolerated. The SanBio Group, based on the study results, aims to apply for manufacture and marketing approval for SB623 as a regenerative medicine product by utilizing Japan's conditional and time-limited approval system for regenerative medicine products.